Market open
Kenvue /$KVUE
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Kenvue
Kenvue is the world's largest pure-play consumer health company by sales, generating over $15 billion in annual revenue. Formerly known as Johnson & Johnson's consumer segment, Kenvue spun off and went public in May 2023. It operates in a variety of silos within consumer health, such as cough, cold and allergy care, pain management, face and body care, and oral care, as well as women's health. Its portfolio has some of the most well-known brands in the space, including Tylenol, Listerine, Johnson's, Aveeno, and Neutrogena. Despite playing in a fragmented industry with intense competition and changing consumer preferences, many of Kenvue's brands are the global leader in their respective segment thanks to their strong brand power.
Ticker
$KVUE
Sector
Trading on
NYSE
Industry
Personal Care Products
Headquarters
Employees
22,000
ISIN
US49177J1025
Website
Kenvue Metrics
BasicAdvanced
$46B
43.30
$0.55
0.97
$0.82
3.43%
Price and volume
Market cap
$46B
Beta
0.97
52-week high
$25.17
52-week low
$17.67
Average daily volume
19M
Dividend rate
$0.82
Financial strength
Current ratio
0.857
Quick ratio
0.505
Long term debt to equity
63.513
Total debt to equity
88.043
Dividend payout ratio (TTM)
147.82%
Interest coverage (TTM)
6.33%
Management effectiveness
Return on assets (TTM)
6.54%
Return on equity (TTM)
10.22%
Valuation
Price to earnings (TTM)
43.299
Price to revenue (TTM)
2.988
Price to book
4.56
Price to tangible book (TTM)
-5.98
Price to free cash flow (TTM)
31.665
Dividend yield (TTM)
3.41%
Forward dividend yield
3.43%
Growth
Revenue change (TTM)
-1.19%
Earnings per share change (TTM)
-29.62%
What the Analysts think about Kenvue
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Kenvue stock.
Kenvue Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Kenvue Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Kenvue News
AllArticlesVideos
Third Point details stakes in U.S. Steel, Kenvue in filing
Reuters·15 hours ago
Everyday Care in Action: Thousands of Kenvue Employees Come Together Across 21 Markets to Help Advance Healthier Communities
Business Wire·2 days ago
Kenvue: First Quarter A Sign Of Challenging Times, But Still A Solid Long-Term Play
Seeking Alpha·5 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Market open
Upcoming events
May28
Kenvue
Dividend·Payment
$0.205Per share
FAQs
What’s the current market cap for Kenvue stock?
Kenvue (KVUE) has a market cap of $46B as of May 16, 2025.
What is the P/E ratio for Kenvue stock?
The price to earnings (P/E) ratio for Kenvue (KVUE) stock is 43.3 as of May 16, 2025.
Does Kenvue stock pay dividends?
Yes, the Kenvue (KVUE) stock pays dividends to shareholders. As of May 16, 2025, the dividend rate is $0.815 and the yield is 3.43%. Kenvue has a payout ratio of 147.82% on a trailing twelve-month basis.
When is the next Kenvue dividend payment date?
The next Kenvue (KVUE) dividend payment is scheduled for May 28, 2025.
What is the beta indicator for Kenvue ?
Kenvue (KVUE) has a beta rating of 0.97. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.